Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.24.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets      
Net operating loss carryforwards $ 229,967 $ 230,373  
Orphan drug and research and development credits 62,457 68,646  
Capitalized research and development credits 21,017 15,680  
Deferred revenue 11,223 11,234  
Deferred compensation 10,365 9,620  
Lease liabilities 244 504  
Other, net 3,654 2,494  
Deferred tax liabilities      
Operating lease right-of-use asset (215) (461)  
Others (81) (439)  
Total net deferred tax assets 338,631 337,651  
Less: valuation allowance (338,631) (337,651)  
Deferred tax assets, net of allowance  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (21.00%) (21.00%) (21.00%)
State, net of federal benefit (as a percent) 0.10% 0.00% 2.80%
Valuation allowance (as a percent) 13.90% 20.20% 27.50%
Stock compensation (as a percent) 5.30% 2.50% 5.60%
Orphan drug and research and development credits (as a percent) 0.20% (2.60%) (14.00%)
Other, net (as a percent) 1.50% 1.00% 2.70%
Effective tax rate (as a percent) 0.00% 0.10% 3.60%